🧬 Bio Twitter Weekly Recap 📝 𝕏 Interesting posts/ppl to check out! 👀 👇 Yair Einhorn SparingVision announced positive safety data from Ph 1/2 PRODYGY trial of SPVN06 #BioTech $XBI $NTLA » x.com/yaireinhorn/st… BiopharmIQ by Amp 🎯 Ph2 & Ph3 readouts in Q4 2024 »

A reason to love #biotech: a company approaching the end (low stock price; near "death") can generate >20x return in a few, or even 1 year! Here are some examples: Who will be next? (Added $LBPH/Lundbeck) #learnbiotechinvesting #investing #BiotechPrometheus

Universal masking and social distancing at the start of the pandemic were so effective that they eliminated a strain of flu, and now annual flu vaccines have been redesigned because that strain no longer needs to be included in the shot. Amazing.

Biotech Investor The history of Pembrolizumab being shelved and eventually becoming a mega blockbuster is enough to show you that not only is it not linear, but hard to predict at any point. Imagine $MRK without Pembrolizumab

Join for free: a virtual conf with 1000+ LPs, Family Offices, Funds of Funds, & GPs of VC, PE, RE, & Hedge Funds – Nov 26 on Zoom. $100M+ & $1B+ Single FOs, LPs, FoFs & other investment firms have confirmed their participation. Like & reply "+" to get the invite in DM (we're at

The GLP1-R agonist field is expanding. Here is my infographic describing its current state. Please DM for pdf with links.